AI assistant
RHYTHM PHARMACEUTICALS, INC. — Director's Dealing 2025
Feb 19, 2025
30849_dirs_2025-02-19_ab483ac7-6ddd-4edc-a266-ac0fda483f1c.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: RHYTHM PHARMACEUTICALS, INC. (RYTM)
CIK: 0001649904
Period of Report: 2025-02-14
Reporting Person: Garfield Alastair (Chief Scientific Officer)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2025-02-14 | Restricted Stock Units | $ | A | 26650 | Acquired | Common Stock (26650) | Direct | |
| 2025-02-14 | Stock Options (Right to Buy) | $56.69 | A | 40000 | Acquired | 2035-02-13 | Common Stock (40000) | Direct |
Footnotes
F1: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock.
F2: The restricted stock units vest as to 25% of the total shares on each of February 14, 2026, February 14, 2027, February 14, 2028 and February 14, 2029. The restricted stock units have no expiration date.
F3: The options vest and become exercisable, subject to the Reporting Person's continued service to the Issuer through the applicable vesting date, as to 6.25% of the total number of shares of common stock subject to the options upon the Reporting Person's completion of each successive three months of service to the Issuer after February 14, 2025, such that the option shall be fully vested and exercisable on February 14, 2029.